BSX241220P88000
- 0.25
- -0.01-3.85%
Boston Scientific Newsroom
RBC Raises Price Target on Boston Scientific to $105 From $98, Keeps Outperform Rating
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Express News | Boston Scientific Corp : RBC Raises Target Price to $105 From $98
Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Optimistic Outlook for Boston Scientific's Urology Segment Drives Buy Recommendation
FDA Roundup: December 17, 2024
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
FDA Alerting About Potential Need For Early Device Replacement Of Boston Scientific Accolade Pacemaker Devices; Boston Scientific Announced Recall For Subset Of Accolade Pacemaker Devices With Increased Risk To Permanently Enter Safety Mode
Another Week, Another Index Record | Lkive Stock
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Investing in Boston Scientific (NYSE:BSX) Three Years Ago Would Have Delivered You a 121% Gain
Jim Cramer on Boston Scientific Corporation (BSX): 'A Superior Company'
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Thursday Ends in Index Declines | Wall Street Today
Boston Scientific Is Maintained at Buy by TD Cowen
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock